Abstract:Thalassemia encompasses a group of inherited hemoglobin disorders characterized by reduced or absent production of the α- or β-globin chains, leading to anemia and other complications. Current management relies on lifelong blood transfusions and iron chelation, which is burdensome for patients. This review summarizes the emerging therapeutic potential of modulating microRNAs (miRNAs) to treat thalassemia. MiRNAs are small non-coding RNAs that regulate gene expression through sequence-specific binding to messenger RNAs (mRNAs). While they commonly repress gene expression by binding to the 3' untranslated regions (UTRs) of target mRNAs, miRNAs can also interact with 5'UTRs and gene promoters to activate gene expression. Many miRNAs are now recognized as critical regulators of erythropoiesis and are abnormally expressed in β-thalassemia. Therapeutically restoring levels of deficient miRNAs or inhibiting overexpression through miRNA mimics or inhibitors (antagomir), respectively, has shown preclinical efficacy in ameliorating thalassemic phenotypes. The miR-144/451 cluster is especially compelling for targeted upregulation to reactivate fetal hemoglobin synthesis. Advances in delivery systems are addressing previous challenges in stability and targeting of miRNA-based drugs. While still early, gene therapy studies suggest combinatorial approaches with miRNA modulation may provide synergistic benefits. Several key considerations remain including enhancing delivery, minimizing off-target effects, and demonstrating long-term safety and efficacy. While no miRNA therapies have yet progressed to clinical testing for thalassemia specifically, important lessons are being learned through clinical trials for other diseases and conditions, such as cancer, cardiovascular diseases, and viral. If limitations can be overcome through multi-disciplinary collaboration, miRNAs hold great promise to expand and transform treatment options for thalassemia in the future by precisely targeting pathogenic molecular networks. Ongoing innovations, such as advancements in miRNA delivery systems, improved targeting mechanisms, and enhanced understanding of miRNA biology, continue to drive progress in this emerging field towards realizing the clinical potential of miRNA-based medicines for thalassemia patients.

Investigational drugs in phase I and phase II clinical trials for thalassemia

Established Approaches, Old Issues, New Non-Curative Therapies, and Perspectives on Healing

Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Novel Therapeutic Approaches In Thalassemias, Sickle Cell Disease And Other Red Cell Disorders

Potential Use of MicroRNA Technology in Thalassemia Therapy

[Overview of new approaches to β-thalassemia treatment]

Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia

β-Thalassemia gene editing therapy: Advancements and difficulties

Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial

Therapeutic Relevance of Inducing Autophagy in β-Thalassemia

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

Iron overload: the Achilles heel of β- thalassemia

Anemia and iron overload as prognostic markers of outcomes in β-thalassemia

Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production

Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice

A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia

Global burden and unmet needs in the treatment of transfusion-dependent β-thalassemia

Molecular genetics of β-thalassemia: A narrative review

Systematic review of hematopoietic stem cell gene therapy approach in thalassemia: Comparative analysis in animal models